Brief: Celltrion Wins Patent Ruling In Taiwan Related To Its Rheumatoid Arthritis Biosimilar Drug Truxima
20/09/2022 02:31
Sept 20 (Reuters) - Celltrion Inc 068270.KS :
* CELLTRION: WINS PATENT RULING IN TAIWAN RELATED TO ITS
RHEUMATOID ARTHRITIS BIOSIMILAR DRUG TRUXIMA
Further company coverage: 068270.KS
(Reporting by Joyce Lee)
((JungYoon.Lee@thomsonreuters.com;))
Recent news on Celltrion
See all newsBrief: Celltrion Inc To Acquire 100 Billion Won Worth Of Own Shares
Brief: Celltrion Q1 Operating. Profit 322 Billion Won, Up 115% Y/Y
Brief: Celltrion To Cancel 100 Billion Won Treasury Shares
Brief: Celltrion Plans Phase 3 Clinical Trials For Keytruda Biosimilar With 220 Patients
Brief: Celltrion To Buy 100 Billion Won Of Own Shares